Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...

Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment Up to 50% of patients ...

Intravesical therapy is widely used in practice as an adjuvant treatment for early-stage bladder cancer following surgical transurethral resection. This is because it is a localized treatment that is ...

Credit: J&J. The New Drug Application is supported by data from cohort 2 of the single-arm, phase 2b SunRISe-1 study. The device remains in the bladder and provides a sustained release of gemcitabine ...

Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). Background ...

Chemotherapy should be immediate after TUR in patients with non-muscle invasive disease. Bladder cancer is projected to be the fourth most common cancer diagnosed in 2007 and the eighth most common ...

Patients with nonmuscle-invasive bladder cancer who received intravesical chemotherapy after transurethral resection of bladder tumor had a significantly lower 30-day complication rate compared with ...

In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

Frequent adverse events are associated with bacillus Calmette–Guérin (BCG) therapy; there is a need, therefore, for new therapies to treat superficial bladder cancer effectively and safely. Apaziquone ...

Gemcitabine delivered via intravesical instillation reduced the risk of recurrence in patients with low-grade non-muscle-invasive urothelial cancer, according to results of a randomized phase III ...

July 27, 2022 – A combination of two intravesical chemotherapy drugs – gemcitabine and docetaxel – yields high response rates with good tolerability in patients with high-risk non-muscle-invasive ...